No Data
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Frontier Biotech: Frontier Biotech 2024 Annual Performance Report Announcement
Frontier Biotech 2024 Annual Results Report Announcement
Frontier Biotech (688221.SH): FB3002 Loxoprofen Sodium Patch has received the notification of acceptance for domestic pharmaceutical production registration and marketing license.
On January 20, Gelonghui reported that Frontier Bio (688221.SH) announced that its product under research, FB3002 (a hot melt adhesive patch for the treatment of musculoskeletal joint pain), has received a "Notice of Acceptance" for its generic drug marketing application issued by the National Medical Products Administration. FB3002, a high-end generic drug for the treatment of musculoskeletal joint pain, contains the active ingredient Loxoprofen Sodium, which is a non-steroidal anti-inflammatory pain reliever. Its mechanism of action is to inhibit the activity of cyclooxygenase, thereby suppressing the synthesis of prostaglandins, resulting in good analgesic and anti-inflammatory effects, especially in terms of pain relief.
Frontier Biotech 2024 Annual Performance Forecast
